...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Enhanced immune response by amphotericin B following NS1 protein prime-oral recombinant Salmonella vaccine boost vaccination protects mice from dengue virus challenge
【24h】

Enhanced immune response by amphotericin B following NS1 protein prime-oral recombinant Salmonella vaccine boost vaccination protects mice from dengue virus challenge

机译：NS1蛋白初次口服重组沙门氏菌疫苗加强免疫后两性霉素B增强的免疫反应可保护小鼠免受登革热病毒的攻击

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A recombinant vaccine strain SL3261/pLT105 of attenuated aroASalmonella enterica serovar Typhimurium SL3261 strain expressing a secreted dengue virus type 2 non-structural NS1 and Yersiniapestis F1 (Caf1) fusion protein, rNS1:Caf1, was generated. Immunological evaluation was performed by prime-boost vaccine regimen. Oral immunization of mice with 1x10(9)cfu of SL3261/pLT105 only induced low levels of NS1-specific antibody response and protective immunity following dengue virus challenge. The parenteral NS1 protein priming-oral Salmonella boosting protocol enhanced both NS1-specific serum IgG response and protective efficacy as compared to mice immunized with each type vaccine alone. Addition of an antifungal antibiotic amphotericin B (AmB) to Salmonella vaccine further enhanced the synergic effects of prime-boost vaccine regimen on the elicited NS1-specific serum IgG response and the protective efficacy. Together, the results demonstrated that the rNS1:Caf1 producing Salmonella SL3261/pLT105 strain fails to provide effective protection as an oral vaccine alone despite co-administration of AmB as an adjuvant capable of enhancing the immune responses, and moreover, the protein priming-oral Salmonella vaccine boosting approach in combination with AmB as an immunization regimen may have the potential to be further explored as an alternative approach for dengue vaccine development.
机译：产生了重组的减毒aroAS肠沙门氏菌血清型鼠伤寒沙门氏菌SL3261菌株SL3261 / pLT105，该菌株表达了分泌型2型非登革热NS1和耶尔森氏菌F1（Caf1）融合蛋白rNS1：Caf1。通过初免-加强疫苗方案进行免疫学评估。用1x10（9）cfu的SL3261 / pLT105口服免疫小鼠只能诱导低水平的NS1特异性抗体反应和登革热病毒攻击后的保护性免疫。与单独用每种类型疫苗免疫的小鼠相比，肠胃外NS1蛋白启动口服沙门氏菌加强方案增强了NS1特异性血清IgG反应和保护功效。向沙门氏菌疫苗中添加抗真菌抗生素两性霉素B（AmB）进一步增强了初免-加强型疫苗方案对引发的NS1特异性血清IgG反应的协同作用和保护功效。总之，结果表明，尽管将AmB作为能够增强免疫应答的佐剂并用，而且蛋白初免口服，但生产rNS1：Caf1的沙门氏菌SL3261 / pLT105菌株不能单独作为口服疫苗提供有效的保护。沙门氏菌疫苗强化方法与AmB结合作为一种免疫方案，可能有可能被进一步探索作为登革热疫苗开发的替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号